How to Get Rezdiffra (Resmetirom) in North Carolina

What Is Rezdiffra and Why Does It Matter for North Carolina Patients?

Rezdiffra (resmetirom) is the first FDA-approved drug specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH). The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, making it available by prescription across all 50 states including North Carolina.

North Carolina has a significant MASH burden. According to CDC data on chronic liver disease prevalence, the Southeast carries disproportionate rates of obesity-related liver conditions. An estimated 1.5 to 2 million North Carolinians may have some form of fatty liver disease, and roughly 20% of those cases progress to the inflammatory MASH stage. Before resmetirom, treatment options were limited to lifestyle modification and off-label medications with inconsistent evidence.

The drug works as a thyroid hormone receptor beta (THR-β) agonist. It selectively activates THR-β in the liver without producing the cardiac or bone side effects associated with systemic thyroid hormone excess. This selectivity is what separates resmetirom from older thyroid analogs that failed clinical development due to safety signals at extrahepatic sites.

MAESTRO-NASH Trial Results That Support the Prescription

The key evidence comes from MAESTRO-NASH, a phase 3, double-blind, randomized controlled trial published in the New England Journal of Medicine in February 2024. The trial enrolled 966 participants with biopsy-confirmed MASH and fibrosis stages F1B through F3 across 198 sites in the United States and internationally.

At 52 weeks, 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving 100 mg achieved MASH resolution without worsening fibrosis, compared with 9.7% in the placebo group [1]. That is a roughly threefold increase in histologic response. Fibrosis improvement by at least one stage (with no worsening of the NAFLD Activity Score) occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group versus 14.2% for placebo [1].

Secondary endpoints showed meaningful reductions in liver fat content. MRI-proton density fat fraction dropped by a relative 32.9% in the 100 mg arm versus 3.6% for placebo at week 52 [1]. LDL cholesterol fell approximately 16% from baseline in the active treatment arms, an effect consistent with THR-β activation in hepatocytes.

Dr. Stephen Harrison, a hepatologist and principal investigator on the MAESTRO-NASH trial, stated: "Resmetirom represents a genuine proof-of-concept that targeting liver-specific thyroid hormone pathways can reverse the histologic damage of MASH without the adverse thyroid effects we've seen with earlier compounds" [1].

These data form the clinical foundation that prescribers in North Carolina evaluate when determining patient eligibility.

Who Can Prescribe Rezdiffra in North Carolina?

Any provider holding an active prescriptive license in North Carolina can write a Rezdiffra prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants. North Carolina grants NPs independent prescriptive authority under NCGS § 90-18.2 after meeting collaborative practice requirements, and PAs prescribe under supervisory agreements per NC Medical Board rules.

Hepatologists and gastroenterologists are the most common prescribers, but endocrinologists and primary care physicians with experience managing metabolic liver disease can also initiate therapy. The practical bottleneck is not licensure type. It is clinical familiarity with fibrosis staging and MASH diagnostic criteria.

For North Carolina specifically, academic medical centers like Duke Health, Wake Forest Baptist, and UNC Health have hepatology divisions that evaluate patients for Rezdiffra candidacy. Community gastroenterology practices across the Triangle, Triad, and Charlotte metro areas have also begun prescribing since mid-2024.

A prescriber will typically require at least one of the following before writing the prescription:

• A liver biopsy showing MASH with fibrosis stage F2 or F3
• A FibroScan result with a liver stiffness measurement between 8.0 and 13.9 kPa (suggesting significant fibrosis) combined with an elevated Enhanced Liver Fibrosis (ELF) score above 9.8
• A Fibrosis-4 (FIB-4) index above 1.3 with confirmatory imaging or biomarker panel

The AASLD 2023 practice guidance on MASLD recommends non-invasive testing as a first-line fibrosis assessment tool, and most North Carolina insurers now accept validated non-invasive scores for prior authorization purposes.

Telehealth Access to Rezdiffra in North Carolina

North Carolina permits telehealth prescribing for Rezdiffra under the state's telehealth parity laws. The NC General Assembly codified telehealth coverage requirements in Session Law 2021-26 (HB 149), which requires insurers to reimburse telehealth visits at the same rate as in-person encounters for covered services.

A telehealth prescriber must hold an active North Carolina medical license or a qualifying interstate compact license. The provider can conduct an initial evaluation via synchronous audio-video technology, review existing labs and imaging, and prescribe Rezdiffra if criteria are met. North Carolina does not require an in-person visit before prescribing non-controlled substances.

Telehealth platforms that connect NC patients with hepatology or metabolic disease specialists have expanded since Rezdiffra's approval. These services typically operate on a consultation model: the patient uploads recent labs (liver panel, lipid panel, TSH, CBC), imaging results (FibroScan or MRI-PDFF), and relevant medical records. The specialist reviews these asynchronously or during a live visit, then sends the prescription to the patient's preferred pharmacy.

Wait times vary. Some telehealth platforms can schedule an initial consultation within 3 to 7 days. Prescription issuance after the visit is usually same-day if documentation is complete.

One constraint: telehealth providers cannot order a FibroScan remotely if the patient has never had one. The patient would need to visit a local facility for the elastography measurement, then return to the telehealth platform with results. Locations offering FibroScan in North Carolina include most hospital-affiliated gastroenterology clinics and some independent imaging centers in Raleigh, Charlotte, Durham, Greensboro, and Wilmington.

Labs Required Before Starting Rezdiffra in North Carolina

Prescribers in North Carolina follow the same lab requirements outlined in the Rezdiffra prescribing information from the FDA. The baseline panel serves two purposes: confirming the diagnosis and establishing safety monitoring values.

Standard pre-treatment labs include:

Liver function tests. ALT, AST, alkaline phosphatase, total bilirubin, and albumin. ALT is expected to be elevated in MASH patients. The FDA label notes that resmetirom reduced ALT by a mean of 26% in the MAESTRO-NASH 100 mg arm by week 24 [1].

Thyroid function. TSH and free T4 at baseline. Resmetirom's selective THR-β activation has minimal effect on systemic thyroid status, but baseline values guide interpretation of any subsequent thyroid changes. In MAESTRO-NASH, TSH levels remained within normal limits in 97% of treated patients [1].

Lipid panel. Total cholesterol, LDL, HDL, and triglycerides. Resmetirom's LDL-lowering effect (approximately 13 to 16%) is clinically relevant, particularly for MASH patients with concurrent metabolic syndrome [1].

Complete blood count and basic metabolic panel. Standard safety baselines.

Fibrosis assessment. FibroScan (vibration-controlled transient elastography), ELF score, FIB-4 index, or liver biopsy. Most NC commercial insurers accept a FibroScan value >8.0 kPa plus an ELF score >9.8 as sufficient non-invasive evidence for prior authorization.

Follow-up labs are typically drawn at weeks 12 and 24, then every 6 months. If ALT rises above 5 times the upper limit of normal or symptoms of hepatotoxicity develop, the FDA label recommends discontinuation.

Prior Authorization and Insurance Coverage in North Carolina

Most commercial insurers in North Carolina require prior authorization for Rezdiffra. The list price is approximately $47,400 per year, making PA a near-universal requirement. BlueCross BlueShield of North Carolina (Blue Cross NC), Aetna, Cigna, and UnitedHealthcare each have published or developing medical policies for resmetirom coverage.

Typical PA documentation requirements include:

• Confirmed MASH diagnosis (ICD-10 code K75.81)
• Documented fibrosis stage F2 or F3 by biopsy or validated non-invasive test
• Evidence of prior lifestyle modification attempt (3 to 6 months of documented diet and exercise counseling in some policies)
• Baseline liver function tests and TSH results
• Prescriber specialty or attestation of MASH management experience

North Carolina Medicaid (NC Medicaid Managed Care, administered through Healthy Blue, WellCare, AmeriHealth Caritas, and UnitedHealthcare Community Plan) does not currently cover Rezdiffra for the MASH indication. Coverage exists only for type 2 diabetes-related indications where the drug may be prescribed off-label, a narrow exception that applies to a small subset of patients [2].

For patients facing PA denials, Madrigal Pharmaceuticals offers the Rezdiffra Access Program, which includes a copay assistance card reducing out-of-pocket costs to as low as $0 per month for commercially insured patients, and a patient assistance program for uninsured or underinsured individuals. The program can be accessed through the Madrigal patient support portal or through prescriber-initiated enrollment.

Appeal success rates after initial PA denial have been reported at approximately 40 to 60% when the appeal includes updated non-invasive fibrosis scores and documentation from a specialist. A peer-to-peer review between the prescriber and the insurer's medical director is often the most effective step in overturning a denial.

Pharmacy Options: Retail, Specialty, and 503A Compounding in North Carolina

Rezdiffra is classified as a specialty medication by most pharmacy benefit managers. It is typically dispensed through specialty pharmacies rather than standard retail pharmacies. In North Carolina, specialty pharmacy options include Accredo (Express Scripts), CVS Specialty, Optum Specialty Pharmacy, and AllianceRx Walgreens Pharmacy. These pharmacies handle the PA coordination, ship directly to the patient's home, and provide clinical support calls.

Fulfillment time after PA approval ranges from 3 to 7 business days for most specialty pharmacies in North Carolina. Some patients report faster turnaround (2 to 3 days) when the prescriber's office submits PA electronically through CoverMyMeds or SureScripts platforms.

503A compounding pharmacies in North Carolina are licensed by the NC Board of Pharmacy to compound patient-specific prescriptions. A 503A pharmacy can compound resmetirom if it holds a valid prescription for a specific patient, the pharmacist determines there is a clinical need for a compounded version (such as a dose form not commercially available), and the pharmacy sources resmetirom active pharmaceutical ingredient from an FDA-registered supplier.

In practice, 503A compounding of resmetirom in NC is uncommon because the commercially available tablets (80 mg and 100 mg) cover the approved dosing range. Compounding becomes relevant when a patient needs an adjusted dose for a specific clinical reason or cannot swallow tablets. North Carolina 503A pharmacies may ship compounded products only within state lines unless they also hold 503B outsourcing facility registration.

Transferring an Existing Rezdiffra Prescription to North Carolina

Patients relocating to North Carolina from another state can transfer an existing Rezdiffra prescription under NC Board of Pharmacy regulations. The receiving NC pharmacy contacts the originating out-of-state pharmacy to verify the prescription and remaining refills. Because Rezdiffra is a non-controlled substance, this transfer follows standard prescription transfer protocols.

If the patient's insurance changes during the move, a new prior authorization will likely be required under the new NC-based plan. This is the most common source of delay. Patients should initiate the PA process 2 to 4 weeks before their existing supply runs out.

For patients who were seeing an out-of-state specialist via telehealth, that prescriber must hold a valid North Carolina license to continue writing prescriptions for an NC resident. If they lack NC licensure, the patient will need to establish care with a new in-state or properly licensed telehealth provider.

The American Association for the Study of Liver Diseases (AASLD) guidance on MASH management recommends continuity of care during treatment transitions, as interrupting resmetirom therapy may reverse hepatic improvements gained during treatment [3].

Timeline: From First Appointment to First Dose in North Carolina

The total time from initial clinical evaluation to receiving Rezdiffra at home varies, but a realistic range is 2 to 6 weeks for most North Carolina patients with commercial insurance.

Week 1. Initial consultation (in-person or telehealth). If the patient already has qualifying labs and fibrosis documentation, the prescriber can submit the prescription and PA request on the same day. If not, lab work and FibroScan are ordered.

Weeks 1, 2. Labs and imaging completed. FibroScan availability in North Carolina is generally within 1 to 2 weeks at major gastroenterology practices. Results return same-day for elastography and within 1 to 3 days for blood work.

Weeks 2, 4. Prior authorization review. Commercial insurers in NC typically respond within 5 to 15 business days. If a peer-to-peer review is required, add 3 to 5 business days.

Weeks 3, 5. Specialty pharmacy fulfillment. Once PA is approved, the specialty pharmacy processes and ships the medication within 3 to 7 business days.

Patients with existing documentation from a prior provider can compress this timeline to as few as 10 days. Patients starting from scratch, with no prior fibrosis testing, should plan for the full 4 to 6 week window.

Safety Monitoring and Follow-Up in North Carolina

After initiating Rezdiffra, patients in North Carolina follow the FDA-recommended monitoring schedule. The prescribing label requires liver function tests at baseline, during dose titration, and periodically thereafter. In practice, most NC hepatologists and gastroenterologists draw labs at 12 weeks, 24 weeks, and every 6 months.

The most common adverse events in MAESTRO-NASH were diarrhea (27.0% in the 100 mg group vs. 18.2% placebo) and nausea (21.7% vs. 12.7%) [1]. These gastrointestinal effects were predominantly mild-to-moderate and decreased in frequency after the first 12 weeks. Serious hepatotoxicity was rare, occurring at a similar rate in treatment and placebo arms.

Gallbladder-related events occurred in 3.3% of patients on resmetirom 100 mg versus 1.7% on placebo in the MAESTRO-NASH trial [1]. The AASLD recommends monitoring for biliary symptoms, particularly in patients with pre-existing gallstones or prior cholecystectomy risk factors.

Weight-based dosing applies: patients weighing <100 kg receive 80 mg once daily, and those weighing ≥100 kg receive 100 mg once daily. The tablets should be taken in the morning with food. Dose adjustments for renal or mild hepatic impairment are not required per the current label, though the drug is contraindicated in decompensated cirrhosis (Child-Pugh B or C) [1].